To ensure that a patient’s test is billed to their 2024 health benefits, testing must be started before the end of the year. For exome, genome, or Xpanded testing, if you do not expect parental samples to be received before the end of the year, please contact us at support@genedx.com to determine how to proceed.
Board Member
Joshua Ruch has served on has served on the Board of Directors at GeneDx (formerly Sema4) since November 2017.
Currently, Joshua is also co-founder and CEO of Rho Capital Partners, an investment and venture capital management company based in New York and Palo Alto. Rho’s activities include investing in information technology, communications, new media, health care, and energy technology, as well as investing in private equity funds and public securities. Before co-founding Rho in 1981, Joshua worked as an investment banker at Salomon Brothers in New York.
In addition to GeneDx, Joshua currently serves as a member of the Board of Directors for Enerkem, Fractal Systems, CloudPay, Code Ocean, and Laer.ai. He is also a trustee of the Mount Sinai Health System, Carnegie Hall and the National Humanities Center, and is a member of the Board of Governors of the Technion – Israel Institute of Technology.
Joshua received an MBA from the Harvard Business School and a BSc in electrical engineering from The Technion in Haifa, Israel. He was born in Belgium and grew up in South Africa. Joshua met his wife, Julia, at The Technion and they have three sons and five grandchildren.
